2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate for Aortic Endothelial Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atherosclerosis, a major contributor to cardiovascular diseases, are often ineffective in preventing or reversing the inflammatory and mitochondrial damage that lead to this condition, highlighting the need for new substances that can improve aortic endothelial cell function.
Innovation Solution
The compound 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate is developed, which inhibits inflammatory responses in aortic endothelial cells, reduces IL-6 mRNA levels, protects mitochondrial function, and increases mitochondrial complex I protein expression, thereby preventing the development of atherosclerosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for atherosclerosis are used, then existing therapeutic approaches are applied, but they are ineffective in preventing or reversing inflammatory and mitochondrial damage
Solution Approach 1:
The patent converts the harmful inflammatory response and mitochondrial damage caused by saturated fatty acids into a beneficial target for treatment. By identifying that these harmful processes are driven by specific molecular pathways, the invention develops compounds that specifically inhibit these pathways, thereby converting the understanding of harm into a basis for therapeutic benefit through targeted anti-inflammatory and mitochondrial protective effects
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure to create 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, which has optimized pharmacological properties. The compound's specific molecular parameters (functional groups, stereochemistry, molecular weight) are designed to achieve optimal binding affinity to inflammatory and mitochondrial targets, thereby improving treatment effectiveness while reducing side effects
2Reliability
If new substances are developed to improve aortic endothelial cell function, then anti-atherosclerotic effects are achieved, but the complexity of drug development increases
Solution Approach 1:
The patent achieves multi-functionality with 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, which simultaneously exhibits anti-inflammatory effects, mitochondrial protective effects, and anti-atherosclerotic properties. This single compound addresses multiple pathological mechanisms of atherosclerosis, thereby reducing the need for complex combination therapies and simplifying the overall treatment approach while maintaining high reliability
Data Source
AI summary
The disclosure relates to a compound, 2-(3,4-dihydroxyphenyl)ethyl 3-hydroxybutanoate, for improving aortic endothelial cell function and use thereof. The compound is capable of inhibiting inflammatory response of the human aortic endothelial cells caused by a saturated fatty acid, and preventing an occurrence and progression of atherosclerosis. The compound is capable of reducing human aortic endothelial inflammation caused by a saturated fatty acid, for example, reducing the mRNA levels of interleukin-6 (IL-6), and is capable of effectively protecting the function of mitochondria in human aortic endothelium from being damaged by a saturated fatty acid, for example, increasing the expression of mitochondrial complex I.